Hopes rise that Pfizer COVID-19 vaccine will be authorized for use in children aged 5 to 11 by late October, and Russia suffers worst one-day death toll

Pfizer and German partner BioNTech have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, raising hopes that a key patient group can be added to the program by as soon as late October.